

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Condensed Balance Sheets(Reviewed, Not Audited)
Nine Months Ended September 30, 2015 and 2014

Assets		September 30, 2015		December 31, 2014		Unit : NT\$ Thousands	
		Amount	%	Amount	%	September 30, 2014	%
Current Assets							
1100	Cash and Cash Equivalents	\$ 722,835	7	\$ 795,907	8	\$ 802,577	8
1150	Notes Receivable	386,016	4	341,765	3	339,690	3
1160	Notes Receivable – Related Parties	149,937	1	160,072	2	168,731	2
1170	Accounts Receivable	1,012,894	10	978,370	9	943,400	9
1180	Accounts Receivable – Related Parties	79,376	1	85,694	1	74,759	1
1200	Other Receivables	100,629	1	42,960	-	77,206	1
1210	Other Receivables –Related Parties	164,606	2	161,277	2	170,805	2
1220	Current Income Tax Assets	-	-	1,016	-	2,842	-
130X	Inventories	1,511,120	15	1,547,744	15	1,534,968	15
1410	Prepayments	64,870	1	62,012	1	46,098	-
1460	Non-current classified as held for sale	-	-	202,746	2	-	-
1476	Other Financial Assets- Current	29,924	-	17,722	-	28,921	-
11XX	Total Current Assets	4,222,207	42	4,397,285	43	4,189,997	41
Non-Current assets							
1523	Available-for-sale Financial Assets- Noncurrent	253,715	3	435,782	4	433,845	4
1543	Financial Assets at Cost - Noncurrent	30,710	-	15,710	-	15,710	-
1550	Long-term Investments at Equity	758,315	8	701,450	7	687,265	7
1600	Property, Plant and Equipment	4,283,360	43	4,297,122	42	4,249,416	42
1760	Investment Property	-	-	27,856	-	230,566	2
1780	Intangible Assets	9,049	-	9,900	-	10,365	-
1840	Deferred tax assets	172,894	2	170,585	2	157,182	2
1900	Other Non-current Assets	233,239	2	254,171	2	231,848	2
15XX	Total Non-Current Assets	5,741,282	58	5,912,576	57	6,016,197	59
1XXX	Total Assets	\$ 9,963,489	100	\$ 10,309,861	100	\$ 10,206,194	100

(Continue)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Condensed Balance Sheets(Reviewed, Not Audited)
Nine Months Ended September 30, 2015 and 2014

Liabilities and Shareholders' Equity		September 30, 2015		December 31, 2014		September 30, 2014	
		Amount	%	Amount	%	Amount	%
Unit : NT\$ Thousands							
Current Liabilities							
2100	Short-term Borrowings	\$ 1,159,527	12	\$ 1,269,899	12	\$ 1,232,290	12
2110	Short-Term Notes and Bills Payable	118,000	1	222,978	2	268,000	3
2150	Notes Payable	139,271	1	88,610	1	144,604	2
2170	Accounts Payable	559,347	6	538,031	5	511,682	5
2200	Other Payables	266,427	3	358,314	4	287,611	3
2230	Current Income Tax Liabilities	15,854	-	47,328	1	29,185	-
2250	Short-term Provisions	49,000	1	98,980	1	98,980	1
2300	Other Current Liabilities	35,083	-	36,054	-	38,400	-
21XX	Total Non-Current Liabilities	2,342,509	24	2,660,194	26	2,610,752	26
Non-Current Liabilities							
2540	Long-term Borrowings	1,595,000	16	1,625,000	16	1,805,000	18
2570	Deferred Income Tax Liabilities	143,786	1	131,245	1	128,418	1
2600	Other Non-Current Liabilities	401,663	4	409,870	4	408,590	4
25XX	Total Non-Current Liabilities	2,140,449	21	2,166,115	21	2,342,008	23
2XXX	Total Liabilities	4,482,958	45	4,826,309	47	4,952,760	49
Equity Attributable to Owners of Parent							
Share Capital							
3110	Ordinary Share	2,980,811	30	2,980,811	29	2,980,811	29
Capital Surplus							
3200	Capital Surplus	642,640	7	642,284	6	642,284	6
Retained Earnings							
3310	Legal Reserve	362,229	4	327,457	3	327,457	3
3320	Special Reserve	188,958	2	188,958	2	188,958	2
3350	Unappropriated Retained Earnings	1,152,525	11	1,042,487	10	918,809	9
Other Equity Interest							
3400	Other Interest	133,369	1	303,594	3	197,782	2
3500	Treasury Stock	(28,054)	-	(28,054)	-	(28,054)	-
31XX	Total Equity Attributable to Shareholders of the Parent	5,432,478	55	5,457,537	53	5,228,047	51
36XX	Noncontrolling Interests	48,053	-	26,015	-	25,387	-
3XXX	Total Shareholders' Equity	5,480,531	55	5,483,552	53	5,253,434	51
Significant Contingent Liability&Unrealized Contractual Arrangement							
Total Liabilities & Shareholders' Equity							
3X2X	Total Shareholders' Equity	\$ 9,963,489	100	\$ 10,309,861	100	\$ 10,206,194	100

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Comprehensive Income(Reviewed, Not Audited)
Nine months Ended September 30, 2015 and 2014

Unit : NT\$ Thousands
(EPS: NT Dollars)

Item	For the Three Months Ended September 30				For the Nine Months Ended September 30							
	2	0	1	5	2	0	1	4				
	Amount	%	Amount	%	Amount	%	Amount	%				
4000 Operating Revenue	\$	1,370,991	100	\$	1,274,047	100	\$	4,196,604	100	\$	3,926,260	100
5000 Operating Costs	(996,179)	(73)	(875,869)	(69)	(2,972,512)	(71)	(2,690,385)	(68)
5950 Gross Profit from Operations		<u>374,812</u>	<u>27</u>		<u>398,178</u>	<u>31</u>		<u>1,224,092</u>	<u>29</u>		<u>1,235,875</u>	<u>32</u>
Operating Expenses												
6100 Selling Expenses	(209,918)	(15)	(195,309)	(15)	(635,694)	(15)	(602,871)	(15)
6200 Administrative Expenses	(47,194)	(4)	(35,486)	(3)	(137,104)	(3)	(108,725)	(3)
6300 Research and Development Expenses	(84,867)	(6)	(86,716)	(7)	(246,406)	(6)	(262,158)	(7)
6000 Total Operating Expenses	(<u>341,979)</u>	<u>(25)</u>	(<u>317,511)</u>	<u>(25)</u>	(<u>1,019,204)</u>	<u>(24)</u>	(<u>973,754)</u>	<u>(25)</u>
6900 Net Operating Income		<u>32,833</u>	<u>2</u>		<u>80,667</u>	<u>6</u>		<u>204,888</u>	<u>5</u>		<u>262,121</u>	<u>7</u>
Non- Operating Income and Expenses												
7010 Other Revenue		62,162	5		5,506	-		107,799	3		36,131	1
7020 Other Gains and Losses		28,617	2	(3,908)	-		23,207	1	(8,723)	-
7050 Finance Cost	(9,239)	(1)	(11,359)	(1)	(28,745)	(1)	(34,440)	(1)
7060 Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method)		26,099	2		7,303	1		96,055	2		38,438	1
7000 Total Non-Operating Income and Expenses		<u>107,639</u>	<u>8</u>	(<u>2,458)</u>	<u>-</u>		<u>198,316</u>	<u>5</u>		<u>31,406</u>	<u>1</u>
7900 Income Before Income Tax		<u>140,472</u>	<u>10</u>		<u>78,209</u>	<u>6</u>		<u>403,204</u>	<u>10</u>		<u>293,527</u>	<u>8</u>
7950 Income Tax Expense	(19,498)	(1)	(13,177)	(1)	(74,877)	(2)	(69,756)	(2)
8200 Net Income	\$	<u>120,974</u>	<u>9</u>	\$	<u>65,032</u>	<u>5</u>	\$	<u>328,327</u>	<u>8</u>	\$	<u>223,771</u>	<u>6</u>
Other Comprehensive Income that will be Reclassified to Profit or Loss												
8361 Exchange Differences on Translation of Foreign Financial Statements	\$	48,999	4	\$	26,487	2	\$	18,564	-	\$	7,959	-
8362 Unrealised Gains (Losses) on Valuation of Available-for-sale Financial Assets	(96,465)	(7)		4,651	-	(182,067)	(4)		86,685	2
8370 Share of Other Comprehensive Income (Loss) of Subsidiaries and Associates Equity Method - Will be Reclassified to Profit	(2,243)	-	(2,380)	-	(3,566)	-	(2,483)	-
8399 Income Tax Relating to Components of Other Comprehensive Income	(8,330)	(1)	(4,503)	-	(3,156)	-	(1,353)	-
8300 Net Other Comprehensive Income and Loss After Tax	(<u>\$ 58,039)</u>	<u>(4)</u>	\$	<u>24,255</u>	<u>2</u>	(<u>\$ 170,225)</u>	<u>(4)</u>	\$	<u>90,808</u>	<u>2</u>
8500 Total Comprehensive Income	\$	<u>62,935</u>	<u>5</u>	\$	<u>89,287</u>	<u>7</u>	\$	<u>158,102</u>	<u>4</u>	\$	<u>314,579</u>	<u>8</u>
Net Income (Losses) Attributable to:												
8610 Shareholders of the Parent	\$	<u>118,829</u>	<u>9</u>	\$	<u>63,903</u>	<u>5</u>	\$	<u>323,659</u>	<u>8</u>	\$	<u>221,204</u>	<u>6</u>
8620 Non-controlling Interests	\$	<u>2,145</u>	<u>-</u>	\$	<u>1,129</u>	<u>-</u>	\$	<u>4,668</u>	<u>-</u>	\$	<u>2,567</u>	<u>-</u>
Comprehensive Income Attributable to:												
8710 Shareholders of the Parent	\$	<u>60,790</u>	<u>4</u>	\$	<u>88,592</u>	<u>7</u>	\$	<u>153,434</u>	<u>4</u>	\$	<u>312,554</u>	<u>8</u>
8720 Non-controlling Interests	\$	<u>2,145</u>	<u>-</u>	\$	<u>695</u>	<u>-</u>	\$	<u>4,668</u>	<u>-</u>	\$	<u>2,025</u>	<u>-</u>
Earnings per Share												
9750 Diluted Earnings Per Share	\$		<u>0.40</u>	\$		<u>0.21</u>	\$		<u>1.09</u>	\$		<u>0.74</u>

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statement of Changes in Equity (Reviewed, Not Audited)
Nine months Ended September 30, 2015 and 2014

Unit : NT\$ Thousands

	T o t a l	E q u i t y		A t t r i b u t a b l e			t o			O w n e r s		o f		P a r e n t
		Ordinary Share	Capital	Surplus	Retained	Earnings	Unappropriated Retained Earnings	Exchange Differences on Translation	Other Equity	Total	Non-controlling Interests	Total Equity		
January 1st to September 30, 2014														
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 63,571	\$ 303,422	\$ 188,958	\$ 870,681	\$ 19,597	\$ 86,835	(\$ 28,054)	\$ 5,064,237	\$ 24,378	\$ 5,088,615		
Appropriation and Distribution of Retained Earnings of 2013														
Legal Reserve	-	-	-	24,035	-	(24,035)	-	-	-	-	-	-		
Cash Dividends	-	-	-	-	-	(149,041)	-	-	-	(149,041)	-	(149,041)		
Subsidiaries Acquired Cash Dividend Payment of Parent Company	-	-	297	-	-	-	-	-	-	297	117	414		
Comprehensive Income (Loss)	-	-	-	-	-	221,204	-	-	-	221,204	2,567	223,771		
Other Comprehensive Income (Loss)	-	-	-	-	-	-	6,651	84,699	-	91,350	(542)	90,808		
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	(1,133)	(1,133)		
Balance, September 30, 2014	<u>\$ 2,980,811</u>	<u>\$ 578,416</u>	<u>\$ 63,868</u>	<u>\$ 327,457</u>	<u>\$ 188,958</u>	<u>\$ 918,809</u>	<u>\$ 26,248</u>	<u>\$ 171,534</u>	<u>(\$ 28,054)</u>	<u>\$ 5,228,047</u>	<u>\$ 25,387</u>	<u>\$ 5,253,434</u>		
January 1st to September 30, 2015														
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 63,868	\$ 327,457	\$ 188,958	\$ 1,042,487	\$ 63,345	\$ 240,249	(\$ 28,054)	\$ 5,457,537	\$ 26,015	\$ 5,483,552		
Appropriation and Distribution of Retained Earnings of 2014														
Legal Reserve	-	-	-	34,772	-	(34,772)	-	-	-	-	-	-		
Cash Dividends	-	-	-	-	-	(178,849)	-	-	-	(178,849)	-	(178,849)		
Subsidiaries Acquired Cash Dividend Payment of Parent Company	-	-	356	-	-	-	-	-	-	356	141	497		
Comprehensive Income (Loss)	-	-	-	-	-	323,659	-	-	-	323,659	4,668	328,327		
Other Comprehensive Income (Loss)	-	-	-	-	-	-	15,550	(185,775)	-	(170,225)	-	(170,225)		
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	17,229	17,229		
Balance, September 30, 2015	<u>\$ 2,980,811</u>	<u>\$ 578,416</u>	<u>\$ 64,224</u>	<u>\$ 362,229</u>	<u>\$ 188,958</u>	<u>\$ 1,152,525</u>	<u>\$ 78,895</u>	<u>\$ 54,474</u>	<u>(\$ 28,054)</u>	<u>\$ 5,432,478</u>	<u>\$ 48,053</u>	<u>\$ 5,480,531</u>		

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Cash Flows(Reviewed, Not Audited)
Nine months Ended September 30, 2015 and 2014

Unit : NT\$ Thousands

For the Nine Months Ended September 30

	<u>September, 2015</u>	<u>September, 2014</u>
<u>Cash Flows From (Used in) Operating Activities</u>		
Consolidated Profit (Loss) Before Tax	\$ 403,204	\$ 293,527
Adjustments		
Depreciation expense	179,649	157,611
Amortized Expense	1,331	502
Bad Debts Recognized Revenue	(563)	3,425
Decrease in Allowance for Sales Returns and Allowances	1,799	(41,791)
Interest Expense	28,745	34,440
Interest Revenue	(9,098)	(12,876)
Dividend Revenue	(11,013)	(6,351)
Share of gain (loss) of Associates and Joint Ventures Accounted for Using Equity Method	(96,055)	(38,438)
Gain on Disposal of Investment	-	(743)
Gain on Disposal of Property, Plant and Equipment	(36,692)	(1,123)
Notes Receivable (Include Related Parties)	(30,128)	63,160
Accounts Receivable (Include Related Parties)	(30,737)	28,917
Other Receivable (Include Related Parties)	5,882	(33,399)
Inventories	43,658	(76,074)
Prepayments	(3,099)	9,104
Notes Payable	48,142	28,578
Accounts Payable	16,212	(16,812)
Other Payable	(61,208)	(93,511)
Short-term Provision	(49,980)	-
Other Current Liabilities	(1,043)	5,342
Other Non-Current Liabilities	(9,962)	(8,310)
Cash Inflow (Outflow) Generated from Operations	389,044	295,178
Interest Received	9,121	10,847
Cash Dividends Received	46,637	49,515
Interest Paid	(29,450)	(34,373)
Income Taxes Refund (Paid)	(98,449)	(52,214)
Net Cash Flows from (used in) Operating Activities	316,903	268,953

(Continue)

China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries
Consolidated Statements Of Cash Flows(Reviewed, Not Audited)
Nine months Ended September 30, 2015 and 2014

Unit : NT\$ Thousands

For the Nine Months Ended September 30

	<u>September, 2015</u>	<u>September, 2014</u>
<u>Cash Flows From (Used in) Investing Activities</u>		
Decrease(Increase) in Financing Receivable	(\$ 56,666)	(\$ 60,816)
Decrease(Increase) in Pledged Deposit	(12,202)	(6,117)
Disposal of Financial Assets in Available-for-sale	-	4,096
Acquired Financial Assets at Cost - Noncurrent	(15,000)	(15,000)
Purchase of Property, Plant and Equipment	(182,170)	(230,309)
Disposal of Property, Plant and Equipment	239,459	5,648
Purchase of Investment Property	-	(1,202)
Decrease(Increase) in Refundable Deposits	(1,353)	11,013
Decrease(Increase) in Prepaid Investment	30,000	-
Decrease(Increase) in Other Non-current Assets		
Acquired Government Grants	-	19,215
Decrease(Increase) in Other Non-current Assets		
Acquired Government Grants	-	137,168
Net Cash Flows From (Used in) Investing Activities	2,068	(136,304)
<u>Cash flows from (used in) Financing Activities</u>		
Decrease(Increase) In Short-term Borrowings	(158,682)	(280,709)
Decrease(Increase) in Short-term Notes and Bills Payable	(54,978)	35,076
Proceeds from Long-term Borrowings	550,000	920,000
Repayment of Long-term Borrowings	(580,000)	(670,000)
Decrease(Increase) in Guarantee Deposits Received	1,386	(1,792)
Assigned Cash Dividends	(178,849)	(149,041)
Acquired Cash Dividends By Minority Interest	(2,771)	(1,133)
Non-controlling Interests change	20,000	-
Net cash FlowsFrom (Used in) Financing Activities	(403,894)	(147,599)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	11,851	(1,128)
Net Increase (Decrease) In Cash and Cash Equivalents	(73,072)	(16,078)
Cash and Cash Equivalents at Beginning of Period	795,907	818,655
Cash and Cash Equivalents at End of Period	\$ 722,835	\$ 802,577